The global antibody drug conjugates market size was valued at USD 11.84 billion in 2024 and is projected to reach from USD 12 ...

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion ...

Exclusive global license outside of Greater Chinafor MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) ...

The "Antibody Drug Conjugates Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.World revenue for the Antibody Drug Conjugates Market is set to surpass US$16 billion in 2025 ...

Celltrion targets innovative drug development with new ADC and antibody candidates Celltrion aims for growth by venturing ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan ...

Zai Lab Limited (ZLAB) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation or ODD to ZL-1310, a ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the U.S. regulatory finish line. The FDA has greenlighted the drug ...

(9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by ...

InveniAI LLC, a global leader in the application of artificial intelligence (AI), machine learning (ML), and generative AI tools to revolutionize drug discovery and development, today announced ...

Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...